Cat. No.: HY-124284

Hexamethylene bisacetamide

(Synonyms: HMBA)

Customer Review

Based on 1 Customer Validation

Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice.

For research use only. We do not sell to patients.

Purity: 99.56%
CAS No.: 3073-59-4
Formula: C₁₀H₂₀N₂O₂
Molecular Weight:200.28

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Hexamethylene bisacetamide Chemical Structure

CAS No.: 3073-59-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All p38 MAPK Isoforms :

All Akt Isoforms :

All NF-κB Isoforms :

All Bcl-2 Family Isoforms :

All Epigenetic Reader Domain Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Erythroleukemia cell line	IC₅₀	5 mM Compound: Fig 5, Cpd 3	Anticancer activity against mouse Erythroleukemia cell line assessed as inhibition of cell growth Anticancer activity against mouse Erythroleukemia cell line assessed as inhibition of cell growth	[PMID: 34591474]
HL-60	IC₅₀	4 mM Compound: HMBA 1	The compound was evaluated in vitro for cytotoxicity against HL-60 cell lines The compound was evaluated in vitro for cytotoxicity against HL-60 cell lines	10.1016/S0960-894X(01)80996-3

In Vitro

Hexamethylene bisacetamide (2.5-10 mM; 15 days) significantly inhibits the proliferation of SHG-44 cells in a dose-dependent manner, but the inhibitory effect is reversible^[2].
Hexamethylene bisacetamide (5-10 mM; 15 days) changes the morphology of SHG-44 cells and increases the degree of cell differentiation^[2].
Hexamethylene bisacetamide (1-20 mM; 30-480 minutes) inhibits the activation of MAPK, Akt signaling pathways and NF - κB in TNFα-treated A549 cells^[3].
Hexamethylene bisacetamide (5 mM; 2 h-7 days) induces apoptosis through Notch1, Bcl - 2 and p53 signaling pathways in Molt4 cells^[4].
Hexamethylene bisacetamide (0.1 mM; 2 h) regulates the expression of neuropeptides through MYH9 and ACTG1 in hypothalamic cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

Human malignant glioma cell line SHG-44
Concentration:

2.5, 5, 7.5 and 10 mM
Incubation Time:

15 days
Result:

Reduced cell proliferation compared with the control group.

Western Blot Analysis^[3]

Cell Line:

A549 cells
Concentration:

10 mM
Incubation Time:

30, 60, 120 and 240 min
Result:

Inhibited the phosphorylation levels of p44/p42 MAPK and MEK1/2.
Inhibited the phosphorylation levels of Akt.

Western Blot Analysis^[4]

Cell Line:

Molt4 cells
Concentration:

5 mM
Incubation Time:

2 h, 4 h, 8 h, 24 h, 48 h, 5 days and 7 days
Result:

Reduced the levels of Notch1.

In Vivo

Hexamethylene bisacetamide (1000 mg/kg intraperitoneal injection; 500-1000 mg/kg intravenous injection; 400 nmoles 2 μL intracerebroventricular injection; 7 days) has an improved effect in mouse obesity model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice with diet-induced obese (DIO) model^[5]
Dosage:

1,000 mg/kg (i.p.);
500 and 1,000 mg/kg (i.v.);
400 nmoles 2 μL (ICV)
Administration:

Intraperitoneal injection (i.p.); 7 days
Intravenous injection (i.v.); 7 days
Intracerebroventricular injection (ICV); 7 days
Result:

Ameliorated obese phenotype in DIO mice, reduced weight gain and food intake and improved metabolic parameters in whatever injection way.
Did not cause sickness behaviors in DIO mice in whatever injection way.
Regulate hypothalamic neuropeptide expression in whatever injection way.

Chemical Information

CAS No. 3073-59-4
Appearance Solid
Molecular Weight 200.28
Formula C₁₀H₂₀N₂O₂
Color White to off-white
SMILES

CC(NCCCCCCNC(C)=O)=O
Synonyms

HMBA
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (499.30 mM; Need ultrasonic)

DMSO : 25 mg/mL (124.83 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.9930 mL

24.9650 mL

49.9301 mL

5 mM

0.9986 mL

4.9930 mL

9.9860 mL

10 mM

0.4993 mL

2.4965 mL

4.9930 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Nilsson LM, et al. Muralidharan SV, Demir D, Welin M, Bhadury J, Logan DT, Walse B, Nilsson JA. Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Res. 2016 Apr 15;76(8):2376-83. [Content Brief]

[2]. Li XN, et al. Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. J Neurosurg. 1996 May;84(5):831-8. [Content Brief]

[3]. Dey A, et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008 Dec;7(23):3759-67. [Content Brief]

[4]. Cecchinato V, et al. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. Leuk Res. 2008 May;32(5):791-7. https://pubmed.ncbi.nlm.nih.gov/17964649/ [Content Brief]

[5]. Park S, et al. HMBA ameliorates obesity by MYH9- and ACTG1-dependent regulation of hypothalamic neuropeptides. EMBO Mol Med. 2023 Dec 7;15(12):e18024. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	4.9930 mL	24.9650 mL	49.9301 mL	124.8252 mL
	5 mM	0.9986 mL	4.9930 mL	9.9860 mL	24.9650 mL
	10 mM	0.4993 mL	2.4965 mL	4.9930 mL	12.4825 mL
	15 mM	0.3329 mL	1.6643 mL	3.3287 mL	8.3217 mL
	20 mM	0.2497 mL	1.2483 mL	2.4965 mL	6.2413 mL
	25 mM	0.1997 mL	0.9986 mL	1.9972 mL	4.9930 mL
	30 mM	0.1664 mL	0.8322 mL	1.6643 mL	4.1608 mL
	40 mM	0.1248 mL	0.6241 mL	1.2483 mL	3.1206 mL
	50 mM	0.0999 mL	0.4993 mL	0.9986 mL	2.4965 mL
	60 mM	0.0832 mL	0.4161 mL	0.8322 mL	2.0804 mL
	80 mM	0.0624 mL	0.3121 mL	0.6241 mL	1.5603 mL
	100 mM	0.0499 mL	0.2497 mL	0.4993 mL	1.2483 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Hexamethylene bisacetamide

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lactylation Compound Library

Anti-Aging Compound Library Mini

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

All p38 MAPK Isoforms

All Akt Isoforms

All NF-κB Isoforms

All Bcl-2 Family Isoforms

All Epigenetic Reader Domain Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs